This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Focus on Alzheimer's Disease and Related Disorders

In This Issue: The Genetic, Transcriptomic, and Proteomic Study of Alzheimer’s Disease

Eric M. Reiman, MD

Published: April 15, 2006

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Last year, we inaugurated a series of occasional research and scholarly review articles with the intent of capturing some of the progress now being made in the scientific understanding, diagnosis, treatment, and prevention of Alzheimer’s disease (AD). In this issue of The Journal of Clinical Psychiatry, Andreas Papassotiropoulos, Michael Fountoulakis, Travis Dunckley, Dietrich Stephan, and I consider the progress now being made in the genetic, transcriptomic, and proteomic study of AD.

Twin studies suggest that about 75% of the risk for late-onset AD may be attributable to heritable risk factors.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 67

Quick Links: Dementia , Neurologic and Neurocognitive

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...